PharmaJet and Diomics partner on SARS-CoV-2 immune response monitoring
GOLDEN, Colo. — November 17, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free Injection System will be used by Diomics, a San Diego-based biotech company, to deliver a biopolymer to detect the formation of an immune response to a SARS-CoV-2 protein. The company was awarded over $2 million by the Department of Defense to accelerate testing of its Diocheck™ system and is expected to begin human clinical trials in December 2020.The Diocheck SARS-CoV-2 Visual Immune Response Indicator provides a simple, universal way to continually monitor a person’s immune response status to COVID-19 over an extended period of time … Details